Group 1: Company Overview and Business Segments - The company focuses on two main business segments: micro-special motors and precision drug delivery devices [3][4] - In the micro-special motors segment, the company is actively expanding its customer base while enhancing automation and intelligent production to reduce costs and improve quality [3] - The precision drug delivery device segment is deepening cooperation with existing strategic clients and exploring new clients, with several customized projects currently in testing and validation stages [3] Group 2: Research and Development Progress - The company has made significant breakthroughs in core technologies for frameless motors, including high torque density magnetic circuit design and high-precision servo control algorithms [2][3] - Continuous investment in R&D is aimed at achieving breakthroughs in the precision drug delivery device sector, leveraging the company's established expertise in micro-special motors [4][8] Group 3: Market Potential and Future Outlook - The future market demand for injection pens is expected to be substantial, particularly in the fields of diabetes and weight loss medications, with significant potential for domestic substitution [6][8] - The company aims to become a leading player in the domestic precision drug delivery device market, capitalizing on its early market entry and comprehensive product line [8] Group 4: Competitive Advantages - The company enjoys a strong customer resource advantage, with a stable market share in the air conditioning sector among major brands like Midea, Gree, and Haier [4] - A robust R&D team with extensive experience in product development and process innovation supports the company's competitive edge [4] - The company adheres to a core value of quality management, which has garnered positive feedback and multiple accolades from clients [4] Group 5: Mergers and Acquisitions Strategy - The company is focused on its core business while seeking quality targets for potential mergers and acquisitions, with plans to disclose any significant developments in accordance with legal regulations [5]

Group 1: Business Overview - The company has established long-term stable partnerships with major home appliance manufacturers such as Midea, Gree, Haier, Hisense, and Aux in the micro motor and components business [1] - The company is focusing on breakthrough core technologies for frameless motors in 2025, aiming to serve the robotics and high-end medical device sectors [1] - The precision drug delivery business is deepening cooperation with existing strategic clients, enhancing customer stickiness [2] Group 2: Market Expansion and Future Plans - In 2024, the company successfully entered the supply chains of well-known enterprises like Xiaomi, Carrier, and Sharp in the micro motor sector [2] - The company plans to accelerate automation and intelligent production transformation in micro motor manufacturing to reduce costs and enhance product competitiveness [2] - The precision drug delivery device business is expanding into new drug areas, including partnerships with major pharmaceutical companies [3] Group 3: Financial Performance - In Q1 2025, the company reported total revenue of ¥113,166,954.09, a year-on-year increase of 2.86% [4] - The net profit attributable to shareholders was ¥7,867,033.66, reflecting a 1.00% increase compared to the same period last year [4] Group 4: Competitive Advantages - The company holds a strong market share in the micro motor sector, particularly in the air conditioning segment, with stable partnerships with leading appliance manufacturers [4] - Continuous investment in R&D has led to breakthroughs in the precision drug delivery device sector [4] - The company emphasizes quality management, which has garnered positive feedback and multiple honors from clients [4]

Group 1: Company Strategy and Goals - The overall business goal is to strengthen precision motors and become a leader in the medical device industry, focusing on technology-driven innovation and market competitiveness [2][3]. Group 2: Market Expansion and Developments - In 2024, the company successfully entered the supply chains of well-known enterprises such as Xiaomi and Sharp, with plans to enhance market penetration and automation in precision motor production [3]. - The precision drug delivery device business generated revenue of 36.76 million yuan in 2024, a decrease of 36.17% year-on-year, primarily due to cyclical orders from clients [4]. Group 3: Financial Performance - In 2024, the company achieved an operating income of 483.41 million yuan, a year-on-year increase of 1.57%, while net profit attributable to shareholders decreased by 48.51% to 33.65 million yuan [8]. - For Q1 2025, operating income reached 113.17 million yuan, a 2.86% increase year-on-year, with net profit growing by 1.00% to 7.87 million yuan [8]. Group 4: Future Plans and R&D - Key plans for 2025 include business expansion, automation of production lines, and breakthroughs in core technologies for frameless motors and high-viscosity drug injection devices [4]. - The company allocated 18.84 million yuan for R&D in 2024, representing 3.90% of operating income, focusing on advanced motor technologies and drug delivery systems [10]. Group 5: Social Responsibility and Customer Relations - The company emphasizes shareholder protection, employee rights, and environmental sustainability, while maintaining strong relationships with major clients like Midea and Gree [5][7].

登录新浪财经APP 搜索【信披】查看更多考评等级 本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者 应当到证监会指定媒体仔细阅读年度报告全文。 所有董事均已出席了审议本报告的董事会会议。 中汇会计师事务所（特殊普通合伙）对本年度公司财务报告的审计意见为：标准的无保留意见。 本报告期会计师事务所变更情况：公司本年度会计师事务所由变更为中汇会计师事务所（特殊普通合 伙）。 非标准审计意见提示 □适用 √不适用 一、重要提示 公司上市时未盈利且目前未实现盈利 □适用 √不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 √适用 □不适用 公司经本次董事会审议通过的利润分配预案为：以5,708.35万股为基数，向全体股东每10股派发现金红 利3.5元（含税），送红股0股（含税），以资本公积金向全体股东每10股转增0股。 董事会决议通过的本报告期优先股利润分配预案 □适用 √不适用 二、公司基本情况 1、公司简介 ■ 2、报告期主要业务或产品简介 （一）主要产品及业务 公司的主营业务为微特电机及应用产品的研发、生产和销售。报告期内，公司微特电机及组件业务占营 业收入的比 ...